Opendata, web and dolomites

Infarnosys

Novel biomarker diagnostic system for the assessment of the prognosis of acute myocardial ischemia/reperfusion injury and infarction and the effectiveness of the treatment

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

Project "Infarnosys" data sheet

The following table provides information about the project.

Coordinator
PHARMAHUNGARY 2000 KISERLETES ES KLINIKAI KUTATASFEJLESZTESI KORLATOLTFELELOSSEGU TARSASAG 

Organization address
address: HAJNOCZY UTCA 6 1 EM 1
city: SZEGED
postcode: 6722
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Hungary [HU]
 Project website http://www.infarnosys.com/
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-1-2015
 Funding Scheme SME-1
 Starting year 2015
 Duration (year-month-day) from 2015-09-01   to  2016-02-29

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    PHARMAHUNGARY 2000 KISERLETES ES KLINIKAI KUTATASFEJLESZTESI KORLATOLTFELELOSSEGU TARSASAG HU (SZEGED) coordinator 50˙000.00

Map

 Project objective

The Infarnosys project aims to launch a novel, combined biomarker diagnostic system on the market that will help clinicians and laboratories to earlier and better diagnose cardiac ischemia/reperfusion injury and prognosticate the effectiveness of the treatment. The innovative process measures MMP-2, MMP-9 and nitrotyrosin levels and tests MMP inhibitors in artery blood samples. Measuring MMP and nitrotyrosin levels enables predicting the occurrence of heart attack and helps to start the treatment much earlier. Testing MMP inhibitors on blood samples will help cardiologists to specify the treatments in a more sophisticated way.

For both men and women, coronary artery disease is the leading cause of death in Europe in spite of the fact that 80% of premature heart diseases are preventable. Earlier and better diagnosis of cardiac ischemia and reperfusion injury is crucial for reducing the number of deaths connected to cardiovascular diseases.

Our diagnostic marker combination has been tested already in a pre-clinical study and the results were published in the European Journal of Clinical Investigation. A Phase 2 project would aim a clinical trial and the Phase 1 feasibility study would prepare it by performing a market research including a market launch strategy and cost analysis, as well as it would prepare the clinical study documentation and the patenting process.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "INFARNOSYS" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "INFARNOSYS" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

PanCareFollowUp (2019)

PanCareFollowUp: Novel, patient-centred survivorship care to improve care quality, effectiveness, cost-effectiveness and accessibility for survivors and caregivers

Read More  

LEGACy (2019)

CeLac and European consortium for a personalized medicine approach to Gastric Cancer

Read More  

CLOSER (2019)

Childhood Leukemia: Overcoming distance between South America and Europe Regions

Read More